NCT01653379View on ClinicalTrials.gov

A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Secondary Hyperparathyroidism
Interventions
DRUG

DP001

DP001 softgel capsules; 55 ng to 550 ng per dose, administered 3 times weekly for 4 weeks

Trial Locations (6)

Unknown

Tucson

Tustin

Denver

St Louis

Greenville

Madison

Sponsors
All Listed Sponsors
lead

Deltanoid Pharmaceuticals

INDUSTRY